186 related articles for article (PubMed ID: 30157201)
1. Relationship between danofloxacin PK/PD parameters and emergence and mechanism of resistance of Mycoplasma gallisepticum in In Vitro model.
Zhang N; Wu Y; Huang Z; Zhang C; Zhang L; Cai Q; Shen X; Jiang H; Ding H
PLoS One; 2018; 13(8):e0202070. PubMed ID: 30157201
[TBL] [Abstract][Full Text] [Related]
2. Determination of the Mutant Selection Window and Evaluation of the Killing of Mycoplasma gallisepticum by Danofloxacin, Doxycycline, Tilmicosin, Tylvalosin and Valnemulin.
Zhang N; Ye X; Wu Y; Huang Z; Gu X; Cai Q; Shen X; Jiang H; Ding H
PLoS One; 2017; 12(1):e0169134. PubMed ID: 28052123
[TBL] [Abstract][Full Text] [Related]
3. The PK-PD Relationship and Resistance Development of Danofloxacin against
Zhang N; Wu Y; Huang Z; Yao L; Zhang L; Cai Q; Shen X; Jiang H; Ding H
Front Microbiol; 2017; 8():926. PubMed ID: 28611739
[No Abstract] [Full Text] [Related]
4. Molecular characterization and typing of enrofloxacin-resistant clinical isolates of Mycoplasma gallisepticum.
Lysnyansky I; Gerchman I; Perk S; Levisohn S
Avian Dis; 2008 Dec; 52(4):685-9. PubMed ID: 19166064
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian Salmonella serovars and their mutants selected during the determination of mutant prevention concentrations.
Kehrenberg C; de Jong A; Friederichs S; Cloeckaert A; Schwarz S
J Antimicrob Chemother; 2007 May; 59(5):886-92. PubMed ID: 17369276
[TBL] [Abstract][Full Text] [Related]
6. Discrepancy between minimal inhibitory concentration to enrofloxacin and mutations present in the quinolone-resistance determining regions of Mycoplasma gallisepticum field strains.
Lysnyansky I; Gerchman I; Levisohn S; Mikula I; Feberwee A; Ferguson NM; Noormohammadi AH; Spergser J; Windsor HM
Vet Microbiol; 2012 Nov; 160(1-2):222-6. PubMed ID: 22655973
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
8. Emergence of a new mutation and its accumulation in the topoisomerase IV gene confers high levels of resistance to fluoroquinolones in Escherichia coli isolates.
Moon DC; Seol SY; Gurung M; Jin JS; Choi CH; Kim J; Lee YC; Cho DT; Lee JC
Int J Antimicrob Agents; 2010 Jan; 35(1):76-9. PubMed ID: 19781915
[TBL] [Abstract][Full Text] [Related]
9. Mutant prevention concentrations of fluoroquinolones against Campylobacter jejuni isolated from chicken.
Wang L; Yuanshu Z; Yuhan Z; Yaojie ; Yingxia L
Vet Microbiol; 2010 Aug; 144(3-4):409-14. PubMed ID: 20226601
[TBL] [Abstract][Full Text] [Related]
10. Fluoroquinolone resistance in Mycoplasma gallisepticum: DNA gyrase as primary target of enrofloxacin and impact of mutations in topoisomerases on resistance level.
Reinhardt AK; Kempf I; Kobisch M; Gautier-Bouchardon AV
J Antimicrob Chemother; 2002 Oct; 50(4):589-92. PubMed ID: 12356806
[TBL] [Abstract][Full Text] [Related]
11. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/Pharmacodynamic Integration to Evaluate the Changes in Susceptibility of
Zhang L; Kang Z; Yao L; Gu X; Huang Z; Cai Q; Shen X; Ding H
Front Microbiol; 2018; 9():2445. PubMed ID: 30369920
[TBL] [Abstract][Full Text] [Related]
13. Emergence of fluoroquinolone-resistant Propionibacterium acnes caused by amino acid substitutions of DNA gyrase but not DNA topoisomerase IV.
Nakase K; Sakuma Y; Nakaminami H; Noguchi N
Anaerobe; 2016 Dec; 42():166-171. PubMed ID: 27793740
[TBL] [Abstract][Full Text] [Related]
14. Mutant-prevention concentrations of enrofloxacin for Escherichia coli isolates from chickens.
Li Q; Bi X; Diao Y; Deng X
Am J Vet Res; 2007 Aug; 68(8):812-5. PubMed ID: 17669019
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
Zhou Y; Yu L; Li J; Zhang L; Tong Y; Kan B
Int J Antimicrob Agents; 2013 Jul; 42(1):72-5. PubMed ID: 23643392
[TBL] [Abstract][Full Text] [Related]
16. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
17. Alterations in DNA gyrase and topoisomerase IV in resistant mutants of Clostridium perfringens found after in vitro treatment with fluoroquinolones.
Rafii F; Park M; Novak JS
Antimicrob Agents Chemother; 2005 Feb; 49(2):488-92. PubMed ID: 15673722
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibilities to fluoroquinolones in current and archived Mycoplasma gallisepticum and Mycoplasma synoviae isolates from meat-type turkeys.
Gerchman I; Lysnyansky I; Perk S; Levisohn S
Vet Microbiol; 2008 Oct; 131(3-4):266-76. PubMed ID: 18534788
[TBL] [Abstract][Full Text] [Related]
20. Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance.
Shimada Y; Deguchi T; Nakane K; Masue T; Yasuda M; Yokoi S; Ito S; Nakano M; Ito S; Ishiko H
Int J Antimicrob Agents; 2010 Sep; 36(3):255-8. PubMed ID: 20580532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
